中国感染与化疗杂志
中國感染與化療雜誌
중국감염여화료잡지
CHINESE JOURNAL OF INFECTION AND CHEMOTHERAPY
2014年
2期
132-134
,共3页
邓晓军%阳辉%欧松%雷湘云%杨炼%郑煜煌
鄧曉軍%暘輝%歐鬆%雷湘雲%楊煉%鄭煜煌
산효군%양휘%구송%뢰상운%양련%정욱황
抗病毒治疗%乙型肝炎病毒%人类免疫缺陷病毒
抗病毒治療%乙型肝炎病毒%人類免疫缺陷病毒
항병독치료%을형간염병독%인류면역결함병독
antiretroviral therapy%hepatitis B virus%human immunodeficiency virus
目的:探讨替诺福韦、拉米夫定、依非韦伦联合方案治疗乙型肝炎病毒/人类免疫缺陷病毒(HBV/HIV)合并感染的疗效和安全性,为临床治疗提供依据。方法对2011年2-10月首次来我院门诊就诊的 HIV/AIDS 患者进行普查,筛选20例符合条件的 HBV/HIV 合并感染者入组,予以替诺福韦、拉米夫定、依非韦伦联合抗病毒治疗,观察其疗效和安全性。结果完成48周观察期的15例患者 HBV DNA 全部阴转,2例出现 HBeAg 血清学转换,肝功能正常;15例 HIV-RNA 低于检测下限,CD4+细胞计数平均增加(139.72±3.36)个/μL;肌酐、乳酸均正常,未发生不良事件。结论替诺福韦、拉米夫定、依非韦伦联合治疗 HBV/HIV 合并感染安全、有效,可作为 HBV/HIV 合并感染患者常规治疗方案。
目的:探討替諾福韋、拉米伕定、依非韋倫聯閤方案治療乙型肝炎病毒/人類免疫缺陷病毒(HBV/HIV)閤併感染的療效和安全性,為臨床治療提供依據。方法對2011年2-10月首次來我院門診就診的 HIV/AIDS 患者進行普查,篩選20例符閤條件的 HBV/HIV 閤併感染者入組,予以替諾福韋、拉米伕定、依非韋倫聯閤抗病毒治療,觀察其療效和安全性。結果完成48週觀察期的15例患者 HBV DNA 全部陰轉,2例齣現 HBeAg 血清學轉換,肝功能正常;15例 HIV-RNA 低于檢測下限,CD4+細胞計數平均增加(139.72±3.36)箇/μL;肌酐、乳痠均正常,未髮生不良事件。結論替諾福韋、拉米伕定、依非韋倫聯閤治療 HBV/HIV 閤併感染安全、有效,可作為 HBV/HIV 閤併感染患者常規治療方案。
목적:탐토체낙복위、랍미부정、의비위륜연합방안치료을형간염병독/인류면역결함병독(HBV/HIV)합병감염적료효화안전성,위림상치료제공의거。방법대2011년2-10월수차래아원문진취진적 HIV/AIDS 환자진행보사,사선20례부합조건적 HBV/HIV 합병감염자입조,여이체낙복위、랍미부정、의비위륜연합항병독치료,관찰기료효화안전성。결과완성48주관찰기적15례환자 HBV DNA 전부음전,2례출현 HBeAg 혈청학전환,간공능정상;15례 HIV-RNA 저우검측하한,CD4+세포계수평균증가(139.72±3.36)개/μL;기항、유산균정상,미발생불량사건。결론체낙복위、랍미부정、의비위륜연합치료 HBV/HIV 합병감염안전、유효,가작위 HBV/HIV 합병감염환자상규치료방안。
Objective To explore the efficacy and safety of tenofovir (TDF)+ lamivudine (3TC)+ efavirenz (EFV)combina-tion therapy in the treatment of HBV/HIV coinfection and provide evidence for effective management of HBV/HIV coinfec-tion.Methods All the AIDS/HIV patients treated in our hospital from February 2011 to October 2011 were screened for eligi-bility in this analysis.Twenty eligible patients with HBV/HIV coinfection were treated with the TDF/3TC/EFV triplet regi-men.The efficacy and safety of the combination therapy were evaluated.Results Of the 15 patients who had completed study period of 48 weeks,all had conversion of HBV DNA to negative,2 had HBeAg seroconversion.The liver function tests were normal.HIV-RNA was below the limit of detection in 15 cases.CD4+ increased by 139.72±3.36/μL on average.The creati-nine and lactate levels were within normal limits.No adverse events were reported.Conclusions The TDF/3TC/EFV triplet regimen is safe and effective for treatment of HBV/HIV coinfection.It is appropriate to recommend this regimen as a standard therapy for HBV/HIV coinfection.